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Summary
Background: Viruses frequently render cells refractory
to subsequent infection with the same virus. This state
of superinfection immunity counteracts potentially det-
rimental consequences for the infected cell and facili-
tates high-level replication and viral spread in the host.
Results: Here, we show that human immunodeficiency
virus (HIV) employs its early gene product Nef to effi-
ciently interfere with superinfection at the viral-entry
step. In this context, we identify the downregulation of
cell-surface CCR5, the major HIV coreceptor, as a novel
and highly conserved activity of Nef. Nef targets the
CCR5 coreceptor and the HIV binding receptor CD4 via
distinct cellular machineries to enhance the endocyto-
sis rate of both HIV receptor components and to accel-
erate their degradation. Functionally, these genetically
separable actions by Nef synergized to efficiently pro-
tect cells from HIV superinfection at the level of fusion
of the viral envelope with the plasma membrane.
Conclusions: HIV has evolved two independent activi-
ties for Nef to downregulate the receptor complex and
to facilitate its efficient replication and spread. This
evasion strategy likely represents a mechanism by
which the pathogenicity factor Nef elevates viral repli-
cation in vivo and thus promotes AIDS pathogenesis.
Introduction
Viruses hijack host-cell machineries to facilitate their
own reproduction. During their replication cycle, vi-
ruses face substantial barriers, such as the host im-
mune system and intracellular antiviral mechanisms. In
addition, they must deal with threats from their own
kind. Once a virus has productively infected a host cell,
additional virus particles engaging the entry receptors
may induce premature death of the cell and endanger
successful viral reproduction [1]. As a consequence,
viruses have evolved strategies to prevent the superin-
fection of cells in which viral replication is already pro-
gressing. Viruses, such as measles virus [2], influenza
virus [3], and hepatitis B virus [4], as well as various
retroviruses, including human immunodeficiency virus
(HIV) [1], appear to prevent superinfection by removing*Correspondence: oliver_fackler@med.uni-heidelberg.de (O.T.F.);
oliver_keppler@med.uni-heidelberg.de (O.T.K.)their entry receptors from the cell surface, a process
known as receptor interference.
In the case of HIV, the downregulation of the binding
receptor CD4 from the surface by viral gene products
has been postulated to interfere with several undesir-
able consequences for the virus; these consequences
include superinfection, induction of proapoptotic sig-
nals delivered through CD4, the triggering of inhibitory
signals for viral transcription, and the mounting of an
HIV-specific immune response (see [5] for review).
Specifically, superinfection is thought to be deleterious
for the infected cell due to the toxicity of accumulating
unintegrated viral genomes [6, 7].
Prior to fusion with the plasma membrane and entry
into target cells, most isolates of the primate lentivi-
ruses HIV type 1 (HIV-1), HIV-2, and simian immunodefi-
ciency virus (SIV) require the sequential interaction of
the gp120 subunit of the viral envelope (Env) glycopro-
tein (GP) with the main cell-surface receptor, CD4, and
subsequently, with the CCR5 coreceptor. The seven-
transmembrane G-protein-coupled chemokine recep-
tor CCR5 is critical for transmission and establishment
of HIV-1 infection in humans [8]. Notably, the cell-sur-
face density of CD4 and CCR5 can be limiting for HIV
infection in vitro and in vivo [9, 10].
Nef is an accessory protein of HIV-1, HIV-2, and SIV
and is a key factor for lentiviral pathogenesis. HIV and
SIV strains lacking functional nef genes fail to replicate
to high titers in vivo, and they either do not cause clin-
ical symptoms or are associated with significantly de-
layed disease progression [11, 12]. Multiple activities of
Nef are thought to synergize to support Nef’s pivotal
role in vivo. As well as downregulating CD4, Nef re-
duces the cell-surface expression of major histocom-
patibility complex class I (MHC-I), and this has been
proposed as a mechanism to facilitate the evasion of
productively infected cells from recognition by cyto-
toxic T lymphocytes [13]. In addition, Nef augments the
infectivity of viral particles and increases the permissiv-
ity of newly infected T cells by elevating their activation
state [14].
It is generally believed that reduced cell-surface CD4
levels induced by Nef result in the protection of infected
cells from HIV superinfection. This assumption is based
on two studies in which HIV-1 replicated less efficiently
in cell lines stably expressing Nef in comparison to the
same cell lines without Nef expression [15, 16]. How-
ever, it was not determined whether this reduced repli-
cation reflected interference with superinfection by Nef
or whether it was mediated by the downmodulation of
CD4 [5]. Here, we report that Nef efficiently protects
cells from HIV superinfection; however, CD4 downregu-
lation does not sufficiently explain this inhibitory activ-
ity of Nef. We find that Nef proteins from human and
simian immunodeficiency viruses downmodulate the
major HIV coreceptor CCR5 from the cell surface and
that this newly discovered Nef activity correlates with
maximum-level resistance to HIV-1 superinfection.
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Expression of HIV-1 Nef Protects Cells from
Superinfection, but Downmodulation of the CD4
Entry Receptor only Partly Accounts
for this Inhibitory Activity
We first examined the effects of Nef expression on the
susceptibility of cells to HIV superinfection. Human
TZM cells expressing a functional Nef.GFP fusion pro-
tein upon adenoviral transduction (see Figure S1C in
the Supplemental Data available with this article online)
were challenged with the CCR5-dependent (R5) HIV-1
strain YU-2. One day later, we scored HIV-1 infection by
staining for the viral p24 capsid antigen and performing
analysis by flow cytometry. Expression of Nef.GFP in-
hibited the HIV susceptibility of cells by 92% relative
to green fluorescent protein (GFP)-expressing controls
(Figure 1A). Surprisingly, NefEDAA.GFP-expressing cells
showed only a partial reversal of the protective effect
on HIV-1 superinfection, with a remaining inhibition of
41%, despite a complete absence of CD4 downregula-
tion by this Nef mutant (Figure 1B) [17]. Thus, to protect
cells from HIV superinfection, Nef employs at least one
mechanism in addition to CD4 downmodulation during
the early phase of the virus–host-cell interaction.
HIV-1 Nef Expression Downmodulates Cell-Surface
Levels of the Chemokine Coreceptor CCR5
Because HIV-1 entry critically depends on the primary
entry receptor CD4 and a human chemokine corecep-
tor, we investigated whether Nef also affects cell-sur-
face levels of the major HIV-1 coreceptor CCR5, which
is utilized by most HIV strains [18]. We examined the
effects of HIV-1 Nef on the steady-state cell-surface
levels of CD4 and CCR5 in chinese hamster ovary
(CHO) hCD4/hCCR5 cells, which stably express high
levels of both human receptors (Figure 1C; see Figure
S2 for primary data on human TZM cells). Compared to
the levels in GFP-expressing control cells (left panels),
CD4 and CCR5 levels were downregulated in a concen-
tration-dependent manner on cells transiently express-
ing Nef.GFP (right panels). To quantify the reductions
induced by Nef, we compared, within the same sample,
receptor levels on non-GFP-expressing cells (gate R2)
with receptor levels on cells with medium GFP-expres-
sion levels (gate R3). Accordingly, Nef.GFP expression
reduced the levels of CCR5 and CD4 on the cell surface
by 70% and 81%, respectively. Thus, HIV-1 Nef induces
a reduction in cell-surface exposure of the entry recep-
tor CD4 and, as a novel finding, also of the major core-
ceptor CCR5.
Nef Downmodulates CCR5 in HIV-1 Infected Cells
via a Ubiquitous Cellular Machinery
Transient expression of Nef induced a marked reduc-
tion in the surface levels of both receptors in several
adherent and T cell lines of human and rodent origin.
The remaining surface levels were 33%–65% and 11%–
38% for CCR5 and CD4, respectively, of the levels of
GFP-expressing control cells (Figure 1D). Notably,
CCR5 was downmodulated with similar efficiency from
the surface of HeLa cells lacking CD4 (Figure 1D, HeLa
hCCR5 or hCD4 transf. [transfected]). This indicatedthat the decrease in CCR5 levels was not simply a con-
sequence of a co-downmodulation with CD4 mediated
by the preassociation of both molecules at the plasma
membrane [19]. Importantly, marked downmodulation
of CCR5 was also detected in activated primary human
peripheral blood lymphocytes (PBLs), which are physi-
ologically relevant target cells for HIV. Nef also down-
modulated cell-surface CCR5 (26%) and CD4 (83%) af-
ter the viral infection of TZM cells (Figure 1E). Similar
results were obtained in activated PBL infected with
HIV-1 from some but not all donors (Figure S3). Thus,
Nef reduces CCR5 cell-surface levels in the context of
HIV replication, and the cellular machinery that Nef ex-
ploits is ubiquitous.
Nef and RANTES Downmodulate CCR5
to Similar Extents
The effect of Nef on CCR5 cell-surface levels was com-
pared to that of the natural CCR5 ligand RANTES (regu-
lated upon activation, normal T cell expressed and
secreted), which potently induces the internalization of
the chemokine receptor and protects cells from R5
HIV-1 infection [20]. Nef.GFP reduced cell-surface
levels of CCR5 and CD4 by 53% and 76%, respectively
(Figure 1F). Overnight treatment of cells with 100 nM of
RANTES resulted in a 51% reduction of surface-CCR5
levels but did not significantly affect surface presenta-
tion of CD4. This degree of RANTES-mediated CCR5
downmodulation was comparable to what has been re-
ported by others [21], and higher concentrations of
RANTES did not further enhance CCR5 downmodula-
tion (data not shown). Thus, expression of Nef reduces
cell-surface levels of CCR5 as efficiently as a natural
β-chemokine ligand does.
Downmodulation of CCR5 Is a Conserved Function
of Lentiviral Nef Proteins
We next compared CCR5 downmodulation by Nef pro-
teins from multiple HIV-1 strains, from HIV-2, and from
SIV (Figure 2A). The reduction of cell-surface CD4 levels
served as an internal reference and ranged between
71% and 79% for the various Nef proteins analyzed.
Remarkably, all Nef proteins significantly reduced
steady-state cell-surface levels of CCR5 with efficien-
cies of 35%–73%. No significant difference in CCR5
downregulation was detected between Nef proteins de-
rived from HIV-1 isolates that use either only CXCR4
(e.g., NL4-3) or both CCR5 and CXCR4 (e.g., SF2) were
used as entry coreceptors. Thus, the ability of Nef to
downmodulate CCR5 is conserved in lentiviral evolu-
tion and is independent of the coreceptor specificity of
the corresponding Env protein.
Nef Employs Distinct Signature Motifs to Regulate
CD4 and CCR5
To identify the molecular determinants required for
CCR5 regulation in Nef, we analyzed several well-char-
acterized HIV-1 Nef mutants [11]. All mutants were ex-
pressed to comparable levels either as GFP fusion pro-
teins or independently of GFP (Figure S1, α-GFP in
panels [A], [B], and [D]). CD4 surface levels were moni-
tored in parallel because critical motifs in Nef and asso-
ciated cellular pathways are well established for CD4
Current Biology
716Figure 1. Nef Downregulates Cell-Surface CCR5 in Addition to CD4
(A) Nef.GFP, NefEDAA.GFP, or GFP alone was transiently expressed by adenoviral transfer in human TZM cells, which stably express CD4
and CCR5. The relative percentage of p24-positive cells for a population of cells with identical GFP intensity was determined by flow
cytometry 21 hr after challenge with the R5 HIV-1 strain YU-2 (1060 ng p24/2.5 × 105 cells). Mean percentages of p24/GFP-double-positive
cells from triplicates + standard deviation (SD) are shown.
(B) CD4 cell-surface levels of cells subjected to adenoviral transfer in parallel to those in (A) prior to HIV challenge. Shown are the mean
fluorescence intensities (MFIs) of viable GFP-positive cells.
(C) CCR5 is downregulated by HIV-1 Nef. Cell-surface levels of human CCR5 and CD4 on Nef.GFP- or GFP-expressing CHO hCD4/hCCR5
cells were analyzed with flow cytometry. Dot plots of GFP expression relative to CCR5 expression (top row) or CD4 expression (bottom row)
are shown.
(D) Nef-mediated CCR5 downregulation is a conserved function in mammalian cells. Various human and nonhuman cell lines that constitutively
coexpress CD4 and CCR5, HeLa cells transiently transfected with either CCR5 or CD4 expression plasmids, and PHA/IL-2-activated primary
human PBL from three donors (activated for 18–21 days) were transfected with expression constructs encoding Nef.GFP or GFP. Two days
after transfection, the MFI for cell-surface-exposed CD4 and CCR5 was quantified on GFP-positive cells in the R3 gate (see panel [C] for
gating) relative to the MFI of GFP-negative cells in the R2 gate. Values obtained for cells expressing GFP alone were set to 100% (SD ranging
from 0.7–8.7). Values are the arithmetic means of triplicates + SD and are representative for three to eight independent experiments.
(E) CCR5 downregulation by Nef in HIV-1-infected cells. TZM cells were infected with VSV-G-pseudotyped HIV-1 R9 env containing either a
wild-type nef gene or an nef deletion (nef). Twenty-four hours after infection, p24-positive cells were analyzed with flow cytometry for cell-
surface levels of CD4 and CCR5. MFI values (arithmetic means of triplicates + SD) of nef-virus-infected cells were set at 100%. Two
comparable experiments were performed.
(F) Nef and the CCR5-ligand RANTES downregulate CCR5 to similar degrees. CCR5 cell-surface levels on CHO hCD4/hCCR5 cells expressing
Nef.GFP (Transfection), GFP (Transfection), or GFP in the presence or absence of RANTES (100 nM for 16 hr) are shown. The GFP control
was set at 100%, and values shown are means of triplicates + SD and are representative for three experiments.downmodulation [11, 13]. Accordingly, nonmyristoy- s
alated Nef (NefG2A mutant) and the NefEDAA and
NefLLAA mutants displayed, in comparison to the wild- i
ttype Nef, less or no activity, respectively, for CD4 down-
regulation (Figure 2B), and mutations in the binding Eites for SH3 domains (NefAxxA mutant) or the sorting
daptor PACS (NefE4A mutant) did not affect the Nef-
nduced reduction in CD4 surface levels. In sharp con-
rast, CCR5 downmodulation was unaffected by the
DAA or LLAA mutations, but the SH3 and PACS in-
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717Figure 2. CCR5 Downregulation Is a Conserved Function of Lenti-
viral Nef Proteins and Occurs via a Mechanism Distinct from CD4
Internalization
(A) Comparison of CCR5 and CD4 downregulation by Nef proteins
from HIV-1, HIV-2, and SIV. Shown are relative cell-surface levels of
both receptors on CHO hCD4/hCCR5 cells expressing the various
Nef proteins from a bicistronic GFP vector. The GFP control was
set to 100%, and values are means of triplicates + SD and are
representative for three independent experiments.
(B) Mapping of Nef’s molecular determinants required for CCR5
downregulation. The relative cell-surface levels of CD4 and CCR5
were determined on CHO hCD4/hCCR5 cells expressing the indi-
cated Nef.GFP fusion proteins. Values shown are means of tripli-
cates + SD and are representative for ten experiments.teraction surfaces as well as the myristoylation were
essential for Nef-mediated regulation of CCR5. In sum-
mary, downmodulation of CD4 and CCR5 is achieved
by genetically separable functions of Nef and is thus
mediated by the interaction with distinct cellular li-
gands.
Nef Enhances the Rate of CCR5 Endocytosis
Nef accelerates the rate of CD4 internalization from the
cell surface [22]. In a kinetic endocytosis assay [23], we
examined the ability of Nef to induce the internalization
of CCR5 from the cell surface. Expression of Nef.GFP
increased the CCR5 internalization rate as compared to
the basal internalization rate detected in GFP-express-
ing control cells (Figure 3A). As expected, RANTES
treatment also enhanced CCR5 internalization, and this
rate was comparable to that of Nef.GFP, particularly
during the early time points. As a control, Nef also me-
diated enhancement of CD4 endocytosis, whereas
treatment with the CCR5 ligand RANTES had no effect
on this receptor (Figure 3B).
Regarding the signature motifs required for this activ-
ity, Nef and the NefEDAA mutant accelerated internal-
ization of CCR5 with comparable efficiencies, but Nef-
AxxA had only a slight effect (Figure 3C). In contrast,
Nef and NefAxxA, but not NefEDAA, markedly en-
hanced the endocytosis rate of CD4 (Figure 3D). Thus,
the Nef determinants required for CCR5 downregula-
tion at steady state also mediate the acceleration of
receptor endocytosis. Furthermore, these results sug-gest enhancement of CCR5 internalization as a key
mechanism by which Nef affects cell-surface levels of
the HIV coreceptor.
Nef Affects the Half-Lives of CCR5 and CD4
Next, we determined whether the Nef-induced internal-
ization of CCR5 results in an enhanced degradation of
the chemokine coreceptor. TZM hCCR5 high cells ex-
pressing Nef.GFP or GFP were radioactively pulse la-
beled and chased for up to 24 hr. In good agreement
with a previous report [22], the half-life, t1/2, of CD4 was
reduced from approximately 6 hr to 3 hr in Nef.GFP-
expressing cells (Figure 3F). The t1/2 of CCR5 molecules
in GFP-expressing control cells was around 24 hr (Fig-
ure 3E). Importantly, Nef expression approximately
doubled the degradation rate of CCR5 and thus re-
sulted in a t1/2 of around 12 hr. The higher molecular
weight of CCR5 at 4–24 hr compared to immediately
after labeling (0 hr) represents the mature, sulphated
form of CCR5 [24]. Notably, we detected no significant
effect of Nef on the quantity of CCR5 or CD4 synthe-
sized during the pulse period (Figures 3E and 3F, 0 hr),
indicating that Nef did not affect the rate of biosynthe-
sis of these receptors. We conclude that expression of
HIV-1 Nef markedly accelerates the degradation of both
CCR5 and CD4.
HIV-1 Nef Targets CCR5 and MHC-I
to a Perinuclear Compartment
Because Nef induces the internalization of CCR5 from
the cell surface and accelerates its degradation, we
used confocal microscopy to explore the subcellular lo-
calization of CCR5 in Nef-expressing cells (Figure 4).
Expression of the NefAxxA.GFP mutant (Figure 4, mid-
dle row) or of GFP alone (data not shown) resulted in a
predominant cell-surface localization of CCR5; this re-
sult is in agreement with the flow-cytometric analyses
(Figure 2B). Conversely, cells expressing Nef.GFP or
NefEDAA.GFP displayed reduced surface levels of
CCR5 and revealed distinct CCR5-containing clusters
in the perinuclear region (Figure 4, upper and lower rows).
Notably, Nef.GFP colocalized with CCR5 in these
clusters.
Nef induces the downmodulation of MHC-I mole-
cules from the surface via the PACS-interaction domain
and targets them to a perinuclear compartment [25,
26]. Because the Nef signature motifs required for
CCR5 and MHC-I downmodulation are identical (Figure
2B), the subcellular localization of MHC-I molecules
was assessed in parallel. In cells expressing Nef.GFP
or the NefEDAA mutant, the surface exposure of MHC-I
was also markedly reduced, and importantly, MHC-I
and CCR5 colocalized to a significant degree in the
perinuclear clusters. Of note, colocalization was not as
pronounced for vesicular structures found toward the
cell periphery. Interestingly, in the presence of Nef, CD4
also accumulated in the perinuclear region and partially
colocalized with CCR5 (Figure S4). In summary, medi-
ated by identical motifs, Nef targets CCR5 and MHC-I
to the same perinuclear compartment where all three
molecules colocalize to a significant extent.
Current Biology
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of CCR5 from the Cell Surface and De-
creases Its Stability
(A–D) Nef enhances the endocytosis rates of
both CCR5 and CD4 in a mutant-specific
manner.
(A and B) Kinetics of decrease of surface-
exposed CCR5 and CD4 in CHO hCD4/
hCCR5 cells expressing Nef.GFP (B) or GFP
alone. GFP-expressing cells were cultivated
in the absence (C) or presence (7) of the
CCR5 ligand RANTES (200 nM). Each data
point represents the mean of duplicates +
SD, and the values at time point 0 were set
to 100%. The experiment shown is represen-
tative for three to five separate experiments.
(C and D) Requirement of interaction sur-
faces of Nef with SH3 domains or the endo-
cytic machinery for accelerated endocytosis
of surface-exposed CCR5 and CD4, respec-
tively. CHO hCD4/hCCR5 cells were ana-
lyzed 1 day after transfection. Results are
representative of three independent experi-
ments.
(E and F) Nef reduces the half-life of CCR5 (E) and CD4 (F). Pulse-chase analysis on TZM hCCR5 high cells after overnight infection with
adeno.Nef.GFP or adeno.GFP are shown. One of two comparable experiments is shown.The protective effect of Nef was specific for superinfec-In GFP-expressing controls, 7.7% of cells were prod-
Figure 4. Nef Induces the Accumulation of
CCR5 in a Perinuclear Compartment, in
which Both Molecules Colocalize with
MHC-I
Subcellular localization of CCR5 and MHC-I
in TZM hCCR5 high cells expressing the indi-
cated Nef.GFP fusion proteins. Shown are
individual confocal sections from the center
of representative cells.Nef Interferes with HIV-1 Superinfection u
Iin a CD4- and CCR5-Dependent Manner
To explore whether the CD4-independent effect on su- c
cperinfection interference by Nef (Figures 1A and 1B)
may be accounted for by CCR5 downregulation, we s
fperformed an HIV superinfection assay (Figure S5) to
assess the activity of Nef wild-type as well as that of E
mthe informative EDAA and AxxA mutants. TZM cells ex-
pressing GFP, Nef.GFP, or the Nef.GFP mutants were b
tchallenged with either HIV-1 R5 YU-2 or an HIV-1
R9env (VSV-G) control virus, and the relative percen- i
wtage of productively infected, p24-positive cells was
scored by flow cytometry. ectively infected by HIV-1 YU-2 (Figures 5A and 5C).
n contrast, Nef.GFP expression almost fully protected
ells from superinfection (0.7% were p24-positive
ells). NefEDAA.GFP, which had no effect on CD4 cell-
urface levels (Figure 5B), still showed 49% protection
rom superinfection (3.8% were p24-positive cells).
qually important is the observation that the NefAxxA
utant, which was deficient in CCR5 downregulation
ut affected CD4 surface levels with an efficiency near
hat of the wild-type (Figure 5B), also displayed a signif-
cant ability to protect cells from superinfection (2.0%
ere p24-positive cells), although this ability was mark-
dly lower than that of Nef.GFP (Figures 5A and 5C).
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tects Cells from Superinfection
(A) Adenovirus-transduced TZM cells ex-
pressing the indicated GFP fusion proteins
were infected with HIV-1 R5 YU-2 (2120 ng
p24/2.5 × 105 cells) (left column) or with VSV-
G-pseudotyped HIV-1 R9env (780 ng p24/
2.5 × 105 cells) (right column). Shown are
relative percentages of p24-positive cells
(closed box) of all cells with comparable GFP
expression levels (closed box + dashed box)
21 hr after HIV infection.
(B) Cell-surface expression of CD4 and
CCR5 12 hr after adenoviral challenge.
(C) Quantification of the superinfection ex-
periment shown in (A) presented as a per-
centage of infected cells relative to the num-
ber of GFP-expressing control cells. Values
shown are arithmetic means of triplicates +
SD and are representative for three indepen-
dent experiments.tion by R5 HIV-1 because the CD4- and CCR5-indepen-
dent superinfection by HIV-1 R9env (VSV-G) was
largely unaffected by the presence of Nef.GFP and its
derivatives (Figure 5A, right panels; Figure 5C, bottom
panel). These results demonstrate that the transient ex-
pression of a wild-type Nef protein is significantly more
effective than the transient expression of its AxxA and
EDAA mutants in protecting cells from HIV superinfec-
tion. From a different perspective, expression of either
the AxxA or the EDAA mutant partially protects cells
from R5 HIV-1 superinfection. This result suggests that
the simultaneous downregulation by Nef of both com-
ponents of the HIV receptor complex may be critical for
the effective protection of cells from superinfection.
The Genetically Separable Functions of Nef
on CCR5 and CD4 Independently and Synergistically
Inhibit Fusion of the Viral Envelope
with the Plasma Membrane
To investigate more directly whether Nef affects the
earliest events in the infection process (i.e., the interac-
tion of HIV Env with the receptor complex and subse-
quent membrane fusion), we performed a cell-to-cell
fusion assay (see Figure S5 for a schematic and Figure
S6 for validation of the assay). CHO Tat cells expressing
various HIV-1 Env proteins were mixed with TZM target
cells, which stably express CD4, CCR5, and a long ter-
minal repeat (LTR)-driven b-galactosidase gene. To as-
say the effects of Nef, we transduced these target cells
with adenoviruses encoding Nef.GFP fusion proteins or
GFP alone, and we quantified the relative β-galactosi-
dase activity as correlate for Env-cell fusion.
Expression of Nef.GFP in TZM target cells drasticallyreduced (by 83%–98%) the cell-to-cell fusion efficiency
for all R5 HIV-1 Envs tested (Figures 6A and S7). Ex-
pression of the Nef EDAA or AxxA mutants also inter-
fered with fusion, and relative efficiencies varied among
the different HIV-1 Envs. For all five HIV-1 Envs, the
higher degree of protection mediated by wild-type Nef
relative to the two Nef mutants suggested an additive
inhibitory effect on fusion for downregulation of both
CD4 and CCR5. To evaluate the use of an X4 HIV-1 Env
as a specificity control for the Nef effect on CCR5, we
analyzed the effects of Nef on surface levels of CXCR4
on TZM cells (Figure 6B). Remarkably, CXCR4 was also
downregulated by Nef with efficiencies comparable to
those seen for CCR5. Consequently, unrelated viral fu-
sion proteins were used as controls, revealing that cell-
cell fusion mediated by the Marburg glycoprotein (Fig-
ure 6A, lower left panel) or the vesicular stomatitis G
protein (VSV-G) (data not shown) was not significantly
affected by the presence of Nef. Together, these results
demonstrate that the transient expression of Nef drasti-
cally and specifically interferes with Env-mediated cell
fusion in HIV.
To address more directly whether the residual fusion
activity in the presence of the NefAxxA.GFP mutant re-
flects the failure of this Nef mutant to downregulate
cell-surface CCR5, we conducted the cell-cell fusion
experiment in the presence of an anti-CCR5 monoclo-
nal antibody (mAb). An anti-CXCR4 antibody served as
an isotype- and coreceptor-specificity control. As seen
in the previously described experiments, expression of
NefAxxA.GFP was less efficient in interfering with cell-
cell fusion than expression of Nef.GFP was, both in the
absence of antibody and in the presence of the anti-
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(A) Fusion efficiencies of TZM target cells expressing the indicated c
GFP or Nef.GFP proteins after they were mixed with CHO Tat cells
expressing the indicated HIV Env proteins were determined via rβ-galactosidase enzyme activity in relation to the protein concen-
stration. Marburg GP served as a fusion control independent of CD4
Hand CCR5. The relative fusion efficiencies of GFP-expressing cells
nwere set to 100%, and the arithmetic means + SD (n = 8) are shown.
The experiment depicted is representative for two to five indepen- a
dent experiments. t
(B) The CXCR4 coreceptor is also downregulated by HIV-1SF2 Nef. e
Shown are relative cell-surface levels of CXCR4 and CD4 on
mNef.GFP- or GFP-expressing TZM cells.
p(C) Fusion efficiencies of cells expressing the indicated GFP or
fNef.GFP proteins after they were mixed with cells expressing Tat
and YU-2 Env. Cells were incubated in the presence of no antibody [
(control), the anti-CCR5 mAb 2D7, or the anti-CXCR4 isotype con- l
trol mAb 12G5 (each 50 g/ml). The arithmetic means of quadrupli- i
cates + SD of Relative Light Units per g protein are shown.
T
d
aCXCR4 control mAb (Figure 6C). Importantly, antibody-
mediated inhibition of CCR5 markedly decreased fu- m
msion activity for both Nef- and NefAxxA-expressing
cells to comparable levels. These results demonstrate t
cthat CCR5 surface levels are a critical component of
the fusion process and are in line with the notion that i
ein NefAxxA-expressing cells, higher levels of surface-
exposed CCR5 are the basis for its weaker protective f
iactivity compared to that of the Nef wild-type-express-
ing cells. In summary, the interference of Nef with su- p
perinfection is to a large degree, if not exclusively, me-
diated by preventing virion-cell fusion. The observed f
ecorrelation between cell-surface downregulation and
superinfection interference strongly suggests that Nef aediates this protection via the simultaneous removal
f both components of the entry receptor-coreceptor
omplex from the cell surface.
iscussion
his study establishes that the accessory protein Nef
f primate lentiviruses efficiently protects cells from su-
erinfection. Although the Nef-mediated downregula-
ion of the primary entry receptor CD4 significantly con-
ributes to this activity, it is insufficient for the maximum
evel of protection. The chemokine receptor CCR5,
hich serves as the major coreceptor for most HIV iso-
ates and whose cell-surface level is critical for virus
ntry, was identified as a novel and functionally impor-
ant target of Nef. Nef downregulated cell-surface-
xposed CCR5 as efficiently as the natural β-chemo-
ine ligand RANTES did.
Notably, the downregulation of CCR5 in the context
f HIV-1 infection was reported in a previous study, al-
hough the responsible viral gene product was not de-
ermined [27]. In the current study, expression of the
arly gene product Nef establishes superinfection im-
unity via mechanistically distinct yet functionally syn-
rgistic strategies that target both components of the
IV receptor complex. Nef downmodulates CCR5 and
D4 from the cell surface by enhancing receptor inter-
alization and degradation via genetically separable
ctivities. Whereas the downmodulation of CCR5 in-
olves the SH3- and PACS-interacting motifs, effects of
ef on CD4 cell-surface levels depend on motifs linked
o the recruitment of the endocytic clathrin-coated ma-
hinery via the c-terminal flexible loop of Nef.
As a result of its ability to internalize the CD4 entry
eceptor, Nef has been suggested to interfere with HIV
uperinfection when expressed in target cells. Indeed,
IV-1 spread over several rounds of replication was sig-
ificantly impaired in stably Nef-expressing cell lines,
n effect that roughly correlated with the ability of Nef
o downregulate CD4 and that was not mediated by
ffects of Nef on HIV transcription [15]. However, this
ay well be the consequence of Nef’s impact on virus
roduction, during which Nef counteracts negative ef-
ects of CD4 on particle release and virion infectivity
28, 29]. In the present study, we now specifically ana-
yzed the immediate effects of Nef expression on the
nfection efficiency of incoming virions in target cells.
hese results provide the first direct experimental evi-
ence that Nef can interfere with HIV superinfection,
nd they indicate that the fusion step at the plasma
embrane is critical for Nef-induced superinfection im-
unity. In light of the discriminatory Nef mutants used,
he removal of cell-surface CD4 was revealed as one criti-
al activity for the prevention of superinfection. Surpris-
ngly, the internalization of CD4 alone was insufficient to
xplain the observed protection of Nef-expressing cells
rom HIV infection, and the entry coreceptor CCR5 was
dentified as a second target critical for Nef-induced su-
erinfection resistance.
Although Nef does not affect CCR5 biosynthesis, ef-
ects on the anterograde transport of CCR5 cannot be
xcluded. The latter mechanism has been suggested
s an additional strategy used by Nef to target MHC-I;
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721however, it may be highly dependent on cell type and
is still a matter of controversy [26, 30]. Notably, MHC-I
is targeted by Nef via the same signature motifs, and
Nef, CCR5, and MHC-I colocalize in a perinuclear com-
partment of the cell, possibly a compartment that rep-
resents the trans-Golgi network [25, 26]. Interestingly,
CD4 also partially colocalized with CCR5 in similar peri-
nuclear structures in Nef-expressing cells. Future ultra-
structural and mechanistic analysis of these structures
will be needed to reveal the identity of these compart-
ments and the exact pathways employed by Nef to
downregulate these various cell-surface receptors.
The Nef determinants identified as critical for CCR5
downregulation have also been implicated in Nef activi-
ties that enhance virion infectivity and virus spread [11].
Importantly, the SH3 and PACS binding motifs in Nef
are required for the full pathogenicity of HIV and SIV in
vivo [31–34]. Until now, this correlation has been inter-
preted as a reflection of Nef’s playing a role in immune
evasion by downmodulating MHC-I [35]. In our study,
levels of Nef-induced CCR5 downregulation in HIV-
infected cells were comparable to those levels in cells
mediating efficient inhibition of HIV superinfection and
Env-cell fusion in the context of adenoviral expression
of Nef. Interestingly, a 25% decrease in surface levels
of CCR5 resulted in a 50% decrease in the suscep-
tibility of target cells to infection. The effect appeared,
on the basis of the phenotype of the EDAA mutant, to
be CD4 independent. Consistent with the nonlinear re-
lationship between the degree of CCR5 downregulation
and functional consequences, recent studies using
RNAi-mediated knockdown of coreceptor molecules
found that a linear decrease in CCR5 or CXCR4 expres-
sion resulted in a logarithmic decrease in cellular infec-
tion or Env-cell fusion, respectively [36, 37]. The current
study maps CCR5 downregulation and maximum-level
protection from superinfection to the identical Nef mo-
tifs, suggesting that this function may be important in
vivo. In line with this notion, Nef-mediated downregula-
tion of CCR5 was detected in HIV-infected primary hu-
man T lymphocytes. However, donor variability and
pleiotropic effects of infection on receptor cell-surface
levels at different stages of the replication cycle (data
not shown) warrant future analyses of this Nef activity
in the context of HIV infection of, for example, primary
macrophages or ex vivo cultures of human tonsils.
One can envision that several consequences of Nef-
induced CCR5 downmodulation may be beneficial for
the virus and enhance viral replication. First, interfer-
ence with superinfection may protect the infected cell
from the accumulation of unintegrated viral genomes
that are cytotoxic and may thus impede virus propaga-
tion [6, 7]. In rendering cells refractory to superinfec-
tion, HIV also facilitates the spread to yet-uninfected
cells by interfering with the loss of newly synthesized
virus particles to cells with an already-established in-
fection. Second, by downmodulating both CCR5 and
CD4 from the surface, HIV may prevent premature in-
teractions with the viral Env, and this may ensure
proper morphogenesis and thus higher infectivity of vi-
ral progeny. Similarly, this downmodulation may count-
eract HIV Env- or β-chemokine-induced signaling events
via CCR5 and CD4, which can induce apoptosis [38–
41] or suppress viral transcription [42]. Third, as an ad-ditional viral-evasion function, CCR5 downmodulation
may inhibit the chemotaxis of infected CD4 T cells to-
ward β-chemokine-secreting cytotoxic T lymphocytes
[20, 43].
From another perspective, the infection of a cell by
more than one virion may favor recombination and thus
viral evolution and fitness. Indeed, infection of cells by
multiple viruses has been reported in patient-derived
lymphocytes [44]. To accommodate these seemingly
juxtaposed outcomes, primate lentiviruses appear to
have evolved time windows during which the permis-
sion or prevention of superinfection is regulated by
gene expression. According to this model, after infec-
tion and prior to early HIV gene expression, superinfec-
tion can readily occur in order to permit recombination.
As the most abundant early viral gene product, Nef de-
fines the starting point of a successful productive infec-
tion and functions as a master switch for the establish-
ment of superinfection resistance by downregulating
the entry receptor complex. Later in the orchestrated
cascade of HIV gene expression, the viral Vpu and Env
proteins also target CD4 [5, 45].
Conclusions
Our findings establish Nef’s role in superinfection resis-
tance and highlight the mechanistically distinct strate-
gies of the pathogenicity factor to target both compo-
nents, CD4 and CCR5, of the HIV entry receptor
complex. This evasion function of Nef likely contributes
to high-level replication of HIV in vivo and thus to
AIDS pathogenesis.
Supplemental Data
Supplemental Data, including Supplemental Experimental Pro-
cedures and seven figures, can be found with this article online at
http://www.current-biology.com/cgi/content/full/15/8/714/DC1/.
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